

Rezalox™ Therapy

CHRONIC PELVIC & BLADDER PAIN

November 2022


- 35 million American women suffer from pelvic pain, painful sex and bladder pain
- 1.1 billion women suffer from these conditions worldwide
- Current treatments remain invasive, painful to receive, have limited efficacy, and often lack sustained pain reduction
- 40% who have major surgeries continue to have pain, and sometimes worse, post-op
- Many end up on narcotics, suffer in silence, while countless others contemplate suicide

This photon energy is called Photobiomodulation Therapy (PBMT):

- Suppresses inflammation within pain triggering, tissues¹
- Relaxes muscle spasms²
- Speeds tissue healing & repair by increasing cellular ATP energy production³
- Increases blood flow & reduces tissue swelling⁴

Patented Rezalox Therapy System:

- Delivers PBMT through the vaginal cavity's walls and into the spasm-laden pelvic floor muscles and the constantly overactive nerves that cannot be surgically excised.
- Has a patent-pending closed-loop CO2 gas cooling system that cools the surface tissues
- Has been engineered and programmed to automatically monitor, respond to, and cool the surface tissues to provide safe and comfortable vaginal treatment sessions.
- Is destined to reduce the dependency of prescription meds (including narcotics), painful procedures & major surgeries.
- Is poised to change the chronic pelvic-bladder pain treatment paradigm and become the standard of care world-wide.
- Upcoming clinical studies to confirm the effectiveness of achieving various states of remission of pain symptoms after a series of six or more treatments



Rezalox Therapy System

Rezalox Therapy System's Handpiece



- Fully enclosed, air and fluid tight
- Capable to administer PBMT both through the vaginal cavity and through the skin's surface.
- CO2 cooling allows higher energy administration while keeping the treatment comfortable.

US Target Market to sell the Rezalox Therapy System

• Gynecologists, Urologists, Urogynecologists, and Pain Clinic Groups	92,300
• Physical Therapists	38,000
• US Hospitals	<u>5,535</u>
TOTAL	135,835

Pool of women who physicians & hospitals would sell a Package of 6 Rezalox Vaginal Treatment Sessions

Chronic Pelvic Pain Sufferers	22 Million
Chronic Bladder Pain Sufferers	8 Million
Painful Intercourse Sufferers	<u>25 Million</u>
TOTAL	55 Million

Investment Capital Raise Round 2 (\$500,000)

- To conduct first-of-its-kind research by February 2023 using our Rezalox Therapy System to determine the depth of laser light energy penetrance (photon fluency) through the unique pelvic soft tissues in female cadavers.
- To perform a human pilot study in women with chronic pelvic pain by summer 2023.
- To enter the US market with our state-of-the-art standalone laser machine targeting physical therapy departments by June 2023

Business Plan

- Randomized Placebo Controlled Trial by fall winter of 2023
- Enter the US market by 2025 with our Rezalox Therapy System with it's enclosed therapy handpiece for treatments through the vaginal cavity and the skin's surface.

Contact Us

Visit our website, RezaloxTherapy.com, which contains scientific information, interviews, articles, and testimonials about PBMT and our Rezalox Vaginal Therapy System.

We welcome the opportunity to meet with those who are interested either in person or via a videoconference meeting to review our business plan, investment pitch deck, and to answer questions about investment materials like the subscription agreement. Please feel free to call, text, or email Dr. Hetz, President and Founder, with questions about this investment opportunity.

Contact Us
GlobalASEReach, LLC
1360 North Union Rd.
Manitowoc, WI 54220
Office (920) 683-1800
Cell (920) 242-2541
N.Hetz@globalasereach.com
RezaloxTherapy.com

1. Laraia, E.M., Silva, I.S., Pereira, D.M., dos Reis, F.A., Albertini, R., de Almeida, P., & Leal Junior, E.C. Effect of Low-Level Laser Therapy (660 Nm) on Acute Inflammation Induced by Tenotomy of Achilles Tendon in Rats. *Photochem Photobiol* 88(6), 1546-1550 (2012).

2. Hamblin, Michael R., & Tatiana N. Demidova. Mechanisms of low-level light therapy. *Mechanisms for low-light therapy*. Vol. 6140. International Society for Optics & Photonics, 2006.

3. Hamblin, Michael R. Mechanisms & applications of the anti-inflammatory effects of photobiomodulation. *AIMS Biophysics* 4.3 (2017): 337.

4. Bjordal, J.M., Johnson, M.I., Iversen, V., Aimbire, F. & Lopes-Martins, R.A. Low-Level Laser Therapy in Acute Pain: A Systematic Review of Possible Mechanisms of Action & Clinical Effects in Randomized Placebo-Controlled Trials. *Photomed Laser Surg* 24(2), 158-168 (2006).